What's Hot
View all perspectives
Dr. Rachel Tate uptoTate
2 years 5 months ago
POS0130 from #EULAR2022 found only a 50% concordance between PsO patients with self-reported MSK pain and US findings of PsA. Remember, not all pain in PsO is PsA. @RheumNow https://t.co/CiMUa9HNgk
Aurelie Najm AurelieRheumo
2 years 5 months ago
🦶🏼What drives positivity of famous Squeeze test in MTPs in RA?
MRI correlation study finds:
-in early RA, association w/
*Synovitis OR 3.2 and Inter-metatarsal bursitis OR 4.8
-in pts in remission
*Sub clinical synovitis only OR 2.5
@RheumNow #EULAR2022
OP0290 https://t.co/2CNUsaesaG
TheDaoIndex KDAO2011
2 years 5 months ago
Prof van Lear defines Difficult to Treat (D2T) RA:
Failed >2 b/tsDMARD w/diff't MOA after failing csDMARD AND signs of active/progressing disease: DAS28 ESR >3.2 or CDAI>10, high ESR/CRP, imaging, Sx's causing low QoL, pred>7.5 mg/d, rapid xray progression #EULAR2022 @rheumnow
Eric Dein ericdeinmd
2 years 5 months ago
Difficult to treat RA? #EULAR2022
1) Active/progressive disease, unable to taper steroids, radiographic progressive, decreased QoL
2) Failure of medications (2+ b/tsDMARD after csDMARD)
3) Physician/patient perception
- Fatigue: not part of definition
~5-20% pts
@Rheumnow https://t.co/i5sfwoF2Gs
Richard Conway RichardPAConway
2 years 5 months ago
When will this madness stop!? TNFi to treat OA (yet again). Adalimumab for "inflammatory" knee OA. And again it doesn't work. @RheumNow #EULAR2022 OP0229 https://t.co/htwyLTYwG4
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#POS0787 #EULAR2022 More data to support the association of Anti-Ribosomal P ab with Depression + Cognitive Dysfunction using functional MRI in #lupus. To screen for neuropsychiatric in ab+ patients @RheumNow https://t.co/9JQDImrHAt
Laurent ARNAUD Lupusreference
2 years 5 months ago
✅ #EULAR2022 positive Phase 2 results for #deucravacitinib (TYK2 inhibitor) in systemic #Lupus with SRI(4) at 32W:
- DEU 3mg BID: 58.2% (p=0.0006)
- DEU 6mg BID: 49.5% (p=0.021)
- DEU 12mg QD: higher (but NS)
vs Placebo 34.4%
+ secondary endpoints.
https://t.co/QCWqW97tre
debaditya_roy debaditya_roy
2 years 5 months ago
#Cytokine #StormHour 🌀🌪️
#EULAR2022
#Great session by Dr.Peter Nigrovic🔥
❓Why sJIA/AOSD often accompanied by MAS❓⚡️
#Always wondered about this!🤔
✅Multiple mechanisms at play
✅Whats New➡️IFN gamma switch
✅mTORC1 is the NEW PIECE in the puzzle of sJIA/AOSD/MAS!🧩🧩 https://t.co/xLzCABunMb
Janet Pope Janetbirdope
2 years 5 months ago
#EULAR2022 quote of the day. I was going to go to the fatigue session @eular_org but I was too tired and burnt out! @RheumNow
Volker Bahr VolkerBahr
2 years 5 months ago
Subcutaneous #methotrexate in #rheumatoidarthritis is safer and better tolerated with better continuation rates than oral #MTX
#eular2022 https://t.co/cjmKntsEMe
debaditya_roy debaditya_roy
2 years 5 months ago
#Lovely slide when deep into the maze of AOSD!🌎🔍❓
#EULAR2022
⚡️Identify level of disease activity
⚡️Systemic/Articular?
⚡️Close monitoring
⚡️Identify non-responders early!
⏲️"DAVID" Project ongoing- validation of EULAR Disease Activity Score in AOSD!
Exciting times ahead!🔥 https://t.co/fuPPj4lEhs
Alberta Hoi alberta_hoi
2 years 5 months ago
I also wonder about the significance of Ro52. Some of the commonly observed features like gastrointestinal dysmotility are not captured. https://t.co/UPljYf65vH
EnvisionRheumat ERheumat
2 years 5 months ago
#EULAR2022
How to Manage (HOT): Lupus Nephritis
Voclosporin is the new CNI
long term reno-ischemic effects need to be looked at https://t.co/8RqayemaRu
EnvisionRheumat ERheumat
2 years 5 months ago
#EULAR2022
WIN session
Sarcoidosis – an update for rheumatologists
Clinical Approach https://t.co/AYOEDsnDZ6
Rheum Cat rheum_cat
2 years 5 months ago
#EULAR2022 COVID orals
OP0172
Swedish COVID19-Reuma registry with n=414 ARD + 61 controls
RTX n=145, ABA n=21
In MVA, use of RTX, ABA were a/w lower Ab response. We've known this about RTX; growing data for ABA as well? https://t.co/Es9bA54m8E
Poster Hall